Related Experiment Video

Updated: Aug 12, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

Methylphenidate improves HIV-1-associated cognitive slowing

C H Hinkin1, S A Castellon, D J Hardy

  • 1Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles 90024, USA. chinkin@ucla.edu

The Journal of Neuropsychiatry and Clinical Neurosciences
|July 13, 2001
PubMed

Insights

Methylphenidate (MPH) may improve cognitive slowing in individuals with HIV-1. The drug showed benefits for those with more significant cognitive or depressive symptoms, but not for those without these deficits.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Infectious Diseases

Background:

  • HIV-1 infection can lead to cognitive slowing and depressive symptoms.
  • Information processing deficits are a significant concern for individuals living with HIV-1.

Purpose of the Study:

  • To evaluate the effectiveness of methylphenidate (MPH) in treating cognitive slowing associated with HIV-1 infection.
  • To determine if MPH impacts depressive symptomatology in this population.

Main Methods:

  • A single-blind, placebo-controlled, crossover study involving 16 HIV-1 seropositive individuals.
  • Participants received 30 mg/day of methylphenidate (MPH) or placebo.
  • Computerized tests measured choice and dual-task reaction time, alongside assessments of depressive symptoms.

Main Results:

  • Participants with greater baseline cognitive slowing or depressive symptoms showed improved reaction times with MPH.
  • Individuals without cognitive slowing at baseline did not exhibit significant improvement with MPH compared to placebo.
  • Methylphenidate (MPH) did not demonstrate a superior effect on depressive symptoms compared to placebo.

Conclusions:

  • Pharmacologic intervention with methylphenidate (MPH), a dopamine agonist, shows potential for treating information processing slowing in HIV-1 infection.
  • Clinical use of MPH may be best reserved for HIV-1 patients presenting with more pronounced cognitive and affective deficits.

More Related Videos

A Rat Model of EcoHIV Brain Infection08:48

A Rat Model of EcoHIV Brain Infection

Published on: January 21, 2021

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice07:23

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice

Published on: December 20, 2024

Related Concept Videos

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...